These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 605913)

  • 1. Apomorphine-stimulated growth hormone release.
    La Rossa JT; Agrin R; Melby JC
    Am J Med; 1977 Dec; 63(6):909-13. PubMed ID: 605913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men.
    Lal S; Martin JB; De la Vega CE; Friesen HG
    Clin Endocrinol (Oxf); 1975 May; 4(3):277-85. PubMed ID: 1149303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual apomorphine as a neuroendocrine probe.
    Brunerova L; Potockova J; Horacek J; Koprivova H; Rehula M; Andel M
    Psychiatry Res; 2012 Jul; 198(2):297-9. PubMed ID: 22394588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone response to low-dose apomorphine in restless legs syndrome.
    Happe S; Bachmann CG; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Growth Horm IGF Res; 2007 Aug; 17(4):323-7. PubMed ID: 17512770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
    Rodriguez M; Lera G; Vaamonde J; Luquin MR; Obeso JA
    J Neurol Neurosurg Psychiatry; 1994 May; 57(5):562-6. PubMed ID: 8201324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of dopaminergic drugs on pituitary hormone release in normal subjects.
    Sekso M; Solter M; Banovac K; Vizner B; Petek M
    Acta Med Iugosl; 1977; 31(4):321-32. PubMed ID: 596235
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectof sex, oral contraceptives, and glucose loading on apomorphine-induced growth hormone secretion.
    Ettigi P; Lal S; Martin JB; Friesen HG
    J Clin Endocrinol Metab; 1975 Jun; 40(6):1094-8. PubMed ID: 1133158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of methyltestosterone on the growth hormone response to the dopamine receptor agonist, apomorphine.
    Lal S; Nair NP; Thavundayil JX; Tawar V; Guyda H; Ayotte C
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(2):263-8. PubMed ID: 1871327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HGH response to dihydroxyphenylalanine (L-dopa) (author's transl)].
    Del Valle Núñez CJ; García Guerrero M; García De Pesquera F; Pérez Bryan J
    An Esp Pediatr; 1976; 9(2):174-9. PubMed ID: 937869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
    Mueller GP; Simpkins J; Meites J; Moore KE
    Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
    Hughes AJ; Lees AJ; Stern GM
    Neurology; 1991 Nov; 41(11):1723-5. PubMed ID: 1944899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC; Sambrook MA; Crossman AR
    Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.